| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | Membrane associated guanylate kinase, WW and PDZ domain containing 2, Activin receptor-interacting protein 1, Acvrip1, Atrophin-1-interacting protein 1 |
| Clonality | |
| Conjugate | |
| Host | |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Overview
Anti-MAGI2/AIP1 Antibody is an antibody targeting Membrane associated guanylate kinase, WW and PDZ domain containing 2, Activin receptor-interacting protein 1, Acvrip1, Atrophin-1-interacting protein 1 Polyclonal raised in Rabbit (Unconjugated). This antibody is commonly used in WB to detect, localize, or compare expression of the target across samples.
Key elements and design rationale
- Target: Membrane associated guanylate kinase, WW and PDZ domain containing 2, Activin receptor-interacting protein 1, Acvrip1, Atrophin-1-interacting protein 1 (also reported as Membrane associated guanylate kinase, WW and PDZ domain containing 2, Activin receptor-interacting protein 1, Acvrip1, Atrophin-1-interacting protein 1).
- Immunogen/epitope region: Intracellular, C-terminus.
- Homology note: Rat, human - identical (informative for cross-species interpretation).
- Species reactivity (as provided): Human, Rat, Mouse.
- Lot quality control (as provided): Western blot analysis.
- Peptide confirmation: Confirmed by amino acid analysis and mass spectrometry.
- Blocking peptide: Available for antigen preadsorption control where appropriate.
- Conjugate/format: Unconjugated (may affect detection channel and background).
These attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.
Biological background
MAGI2 is a member in the Membrane-associated guanylate kinase with an inverted arrangement of protein-protein interaction domains (MAGI) family, and includes two additional family members, MAGI1 and MAGI31.MAGI proteins are essential for efficient cell signaling as they function as scaffolds for assembling cell adhesion molecules, receptors and signaling molecules and linking them to the cytoskeleton2.MAGI2 has a guanylate kinase, 2 WW, and 6 PDZ domains (PDZ0-PDZ5). It interacts with cytoskeleton-associated proteins: guanylate-kinase-associated protein (GKAP), Postsynaptic density-95 (PSD-95)/synapse-associated protein 90 (SAP90), Stargazin/transmembrane AMPAR regulatory proteins (TARPs). MAGI2 also interacts with N-methyl-D-aspartate (NMDA) receptors, δ2 Glutamate receptor, β1AR, VPAC1, Brain-specific angiogenesis inhibitor-1, Activin Type II receptors, Neuroligins, β-Dystroglycan, Dendrite arborization and synapse maturation 1 (Dasm1)/IgSF9b, Nectins and Nephrin receptors and cell adhesion proteins, respectively1,3.MAGI2 expression is almost exclusively in brain, deletion of MAGI2 causes infantile spasm and increased cognitive impairment in schizophrenia patients4.In non-neuronal tissues, MAGI2 enhances the ability of PTEN to suppress Akt activation in the PI3-kinase/Akt pathway.
Research relevance and current trends
- Comparing target expression across perturbations, genotypes, or treatment conditions.
- Interpreting localization shifts alongside pathway or phenotypic readouts.
- Using orthogonal controls (KO/KD, peptide competition, isotype concepts) to support conclusions.
Common research applications
- Western blot (WB): compare target abundance/size across lysates and conditions; consider isoforms/PTMs.
Interpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO/KD) and using orthogonal readouts where feasible.
Notes for experimental interpretation
- Isoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.
- Cross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.
- Permeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.
- Conceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.
- Provided control suggestions: Negative control: BLP-PZ052.
- Application notes: see product-specific dilution/usage notes and control concepts provided in the dataset.
Application abbreviations: CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. Species abbreviations: H- Human, M- Mouse, R- Rat.
Recommended controls: Blocking peptide: BLP-PZ052; Negative control: BLP-PZ052.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
